Brief: Biomarin Pharmaceutical - And N-Lorem Announce Global Exclusive License To Develop Aso Medicine For Renu Syndrome
27/07/2026 14:09
BRIEF-Biomarin Pharmaceutical - And N-Lorem Announce Global Exclusive License To Develop Aso Medicine For Renu Syndrome July 27 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:
BIOMARIN PHARMACEUTICAL - AND N-LOREM ANNOUNCE GLOBAL EXCLUSIVE LICENSE TO DEVELOP ASO MEDICINE FOR RENU SYNDROME
Source text: ID:nPn6mCLm6a
Further company coverage: BMRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife